Outputs (3)

Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics (2017)
Journal Article
Sotgia, F., Fiorillo, M., & Lisanti, M. (2017). Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics. Oncotarget, 2017(8), 68730-68745. https://doi.org/10.18632/oncotarget.19612

Here, we used a data-mining and informatics approach to discover new biomarkers of resistance to hormonal therapy in breast cancer. More specifically, we investigated whether nuclear-encoded genes associated with mitochondrial biogenesis can be used... Read More about Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics.

Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast (2017)
Journal Article
Ozsvari, B., Fiorillo, M., Bonuccelli, G., Cappello, A., Frattaruolo, L., Sotgia, F., …Lisanti, M. (2017). Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. Oncotarget, 2017(8), 67457-67472. https://doi.org/10.18632/oncotarget.19084

The “endo-symbiotic theory of mitochondrial evolution” states that mitochondrial organelles evolved from engulfed aerobic bacteria, after millions of years of symbiosis and adaptation. Here, we have exploited this premise to design new antibiotics an... Read More about Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast.

Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer (2017)
Journal Article
Fiorillo, M., Sotgia, F., Sisci, D., Cappello, A., & Lisanti, M. (2017). Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer. Oncotarget, 2017(8), 20309-20327. https://doi.org/10.18632/oncotarget.15852

Here, we identified two new molecular targets, which are functionally sufficient to metabolically confer the tamoxifen-resistance phenotype in human breast cancer cells. Briefly, ~20 proteins were first selected as potential candidates, based on u... Read More about Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer.